NOVO'S CAGRISEMA WAS ASSOCIATED WITH 25% MEAN WEIGHT LOSS AMONG EARLY RESPONDERS IN A POST HOC ANALYSIS OF REDEFINE 1 PRESENTED AT OBESITYWEEK® 2026

Reuters · 1d ago

Please log in to view news